Singapore: Travecta Therapeutics embarks on broad expansion of board

Travecta Therapeutics, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier and blood-retinal-barrier, has announced the addition of several new members to the board of directors. Donald C Manning is Chief Medical Officer and Head of R&D, Peter Milligan is CFO, Peter Tate is Head of Singapore Operations and Peter…

You must be a HMI Subscriber to view this content.

Subscribe Now »